Medicine
Haroon Moolla, R. Kassanjee, J. Euvrard, G. Maartens, H. Prozesky, Matthew P Fox, C. Orrell, G. Fatti, Frank Tanser, G. Wandeler, Mary-Ann Davies, Reneé de Waal, P. Nyakato, Leigh F. Johnson
Abstract
Viral suppression estimates are essential for monitoring the performance of HIV programmes. South Africa introduced dolutegravir (DTG)‐based antiretroviral therapy (ART) in 2019. We sought to generate updated estimates of viral suppression in South African adults on ART and investigate predictors of viral non‐suppression.
Citation format
MOOLLA, Haroon, et al. Estimates and predictors of HIV viral non‐suppression in south African adults on antiretroviral treatment. Journal of the International AIDS Society, 2026, 29(1): e70076.